NCT03053622View on ClinicalTrials.gov

A Study of Mirikizumab (LY3074828) Injection in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

April 3, 2018

Study Completion Date

April 3, 2018

Conditions
Healthy
Interventions
BIOLOGICAL

Mirikizumab Test

Administered SC

BIOLOGICAL

Mirikizumab Test

Administered IV

BIOLOGICAL

Mirikizumab Reference

Administered SC

Trial Locations (1)

LS2 9LH

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03053622 - A Study of Mirikizumab (LY3074828) Injection in Healthy Participants | Biotech Hunter | Biotech Hunter